Skip to main content

Table 1 Clinical data of 321 ESRD patients on chronic intermittent hemodialysis

From: Dealing with prognostic signature instability: a strategy illustrated for cardiovascular events in patients with end-stage renal disease

Patients  
Age (yrs) 66.3 (± 17.3)
Sex (Male (%) / Female (%)) 197 (61) / 124 (39)
BMI (kg/m 2) 25.2 (± 5.1)
Dialysis  
Time on dialysis at inclusion (months) 49 (± 46)
Dialysis treatment duration per week (hrs) 12.7 (± 2.5)
Kt/V (mean of last three 1.27 (± 0.34)
measurements before inclusion)  
Renal disease  
Diabetic nephropathy (%) 85 (26)
Glomerulonephritis (%) 75 (23)
Hypertensive/Vascular (%) 48 (15)
ADPKD (%) 26 (8)
Other (%) 46 (14)
Unknown (%) 41 (13)
Clinical chemistry  
Total cholesterol (mg/dL) 177 (± 43)
Triglycerides (mg/dL) 197 (± 145)
Hemoglobin (g/dL) 11.7 (± 1.5)
CRP (mg/L) 30.5 (± 71.5)
Urea before dialysis (mg/dL) 121 (± 43)
Phosphate (mean of three predialysis 5.6 (± 1.7)
measurements, mg/dL)  
Total Calcium (corrected for albumin (mmol/L)) 2.3 (± 0.3)
Calcium × Phosphate product 50 (± 14)
Parathormon, in patients not 158 (± 201)
parathyroidectomized (pg/ml)  
Ferritin (ng/mL) 540 (± 332)
Albumin (g/dl) 4.0 (± 0.6)
  1. BMI: Body mass index; ACE-I: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; MI: Myocardial infarction